

A Lifelong Solution
for a Chronic Condition

Shareholders Update – 2021-Q3

Dear shareholders of Paragate Medical, herein is a brief quarterly update:

- **Development:** Paragate has received pending approval from the Israeli Ministry of Health to start the clinical trials of its IPUDx Gen-1 system for treatment of fluid overload in heart failure patients. The ACWR-HF trial will commence in Rambam healthcare campus and will be expanded to additional sites.
- **HR:** Paragate has assigned *Liora Levi, PhD*, as its VP Clinical and Regulatory Affairs, starting August 2021, to lead the upcoming clinical trials and further device generations development. Liora has formerly served as Chief Scientist Officer and Director of Clinical/Regulatory Affairs at Home Skinnovations Ltd.
- **Programs and Collaborations:** Paragate has joined Pennsylvania Drexel University City Science Center's incubation program to support US market validation & business development.
- **Funding:** Paragate has submitted grant application to Israeli Innovation Authority to leverage its private financing and secure runway for completion of the first in human trial.

We would like to thank you for your ongoing support.

The foregoing is, to the best of our knowledge, true and accurate.

Nitai Hanani
CEO

Nizar Mishael
CFO